Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 2:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 182 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Myositis Clear all
Terminated Phase 1 Interventional Results available

Stem Cell Transplantation in Idiopathic Inflammatory Myopathy Diseases

NCT00278564
View directory record Official record
Conditions
MYOPATHY
Interventions
Hematopoietic stem cell transplantation, Cyclophosphamide, Mesna, ATG(rabbit), Methylprednisolone, G-CSF, Rituxan
Biological · Drug
Lead sponsor
Northwestern University
Other
Eligibility
16 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 5, 2018 · Synced Jul 21, 2026, 2:17 PM EDT
Recruiting Phase 1 Interventional

A Study of AZD0120 in Autoimmune Diseases

NCT07295847
View directory record Official record
Conditions
Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis
Interventions
AZD0120
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
8
States / cities
Tucson, Arizona • Stanford, California • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Jul 21, 2026, 2:17 PM EDT
Active, not recruiting No phase listed Observational

Sporadic Inclusion Body Myositis Natural History Study

NCT05046821
View directory record Official record
Conditions
Sporadic Inclusion Body Myositis, Inclusion Body Myositis
Interventions
Not listed
Lead sponsor
University of California, Irvine
Other
Eligibility
40 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
13
States / cities
Los Angeles, California • Orange, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jul 21, 2026, 2:17 PM EDT
Recruiting Phase 2 Interventional

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

NCT06991114
View directory record Official record
Conditions
Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs), Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA, IIM, Myositis, Scleroderma, Sjogren Syndrome, Sjogrens Disease
Interventions
Allogeneic NK Cells
Drug
Lead sponsor
Artiva Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
31
States / cities
Tuscaloosa, Alabama • Phoenix, Arizona • Tucson, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 21, 2026, 2:17 PM EDT
Terminated Early Phase 1 Interventional

COVID-19 Vaccination in Rheumatic Disease Patients

NCT04839315
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Sjogren's Syndrome, Inflammatory Myositis, Psoriatic Arthritis, Gout, Ankylosing Spondylitis, Arthritis of Multiple Sites Associated With Inflammatory Bowel Disease (Diagnosis), Osteoarthritis
Interventions
mRNA COVD19 vaccine
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 2, 2022 · Synced Jul 21, 2026, 2:17 PM EDT
Completed Phase 3 Interventional

Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome

NCT00025818
View directory record Official record
Conditions
Keratoconjunctivitis Sicca, Sjogren's Syndrome, Lupus Erythematosus, Systemic, Arthritis, Rheumatoid, Scleroderma, Systemic
Interventions
Ophthalmic Emulsion
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
17
States / cities
La Jolla, California • Los Angeles, California • Waterbury, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated May 29, 2011 · Synced Jul 21, 2026, 2:17 PM EDT
Completed Early Phase 1 Interventional

Phase 1 Study of ULSC in Patients With Polymyositis (PM) and Dermatomyositis (DM)

NCT04723303
View directory record Official record
Conditions
Polymyositis, Dermatomyositis
Interventions
Umbilical Cord Lining Stem Cells
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Jul 21, 2026, 2:17 PM EDT
Active, not recruiting Phase 2 Interventional

Phase 2 Study of Rapcabtagene Autoleucel in Myositis

NCT06665256
View directory record Official record
Conditions
Idiopathic Inflammatory Myopathies
Interventions
Rapcabtagene autoleucel, Active Comparator Option
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
10
States / cities
Birmingham, Alabama • Zephyrhills, Florida • Augusta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jul 21, 2026, 2:17 PM EDT
Completed No phase listed Observational

An International Cross-sectional Survey to Evaluate the Burden of Fibrodysplasia Ossificans Progressiva (FOP) on Patients and Their Families.

NCT04665323
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva
Interventions
Not listed
Lead sponsor
Ipsen
Industry
Eligibility
Not listed
Enrollment
411 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 20, 2021 · Synced Jul 21, 2026, 2:17 PM EDT
Completed Phase 3 Interventional Results available

A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies.

NCT05027802
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva (FOP)
Interventions
Palovarotene
Drug
Lead sponsor
Ipsen
Industry
Eligibility
14 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
San Francisco, California • Rochester, Minnesota • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 21, 2025 · Synced Jul 21, 2026, 2:17 PM EDT
Completed Phase 2 Interventional Results available

A Study to Examine the Safety, Tolerability and Effects on Abnormal Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva

NCT03188666
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva
Interventions
REGN2477, Matching placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
3
States / cities
Rochester, Minnesota • Philadelphia, Pennsylvania • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Jul 21, 2026, 2:17 PM EDT
Completed No phase listed Observational

Lithium in Inclusion Body Myositis (IBM)

NCT00917956
View directory record Official record
Conditions
Inclusion Body Myositis
Interventions
Not listed
Lead sponsor
Phoenix Neurological Associates, LTD
Other
Eligibility
30 Years to 88 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 25, 2010 · Synced Jul 21, 2026, 2:17 PM EDT
Completed Phase 2 Interventional Results available

A Study In Adults With Moderate To Severe Dermatomyositis

NCT03181893
View directory record Official record
Conditions
Dermatomyositis
Interventions
PF-06823859 low, Placebo Arm, PF-06823859 high
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
35
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Jul 21, 2026, 2:17 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients

NCT01925209
View directory record Official record
Conditions
Sporadic Inclusion Body Myositis
Interventions
BYM338/bimagrumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
36 Years to 85 Years
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
12
States / cities
Phoenix, Arizona • Orange, California • Sacramento, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Jul 21, 2026, 2:17 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Genetic and Family Studies of Inherited Muscle Diseases

NCT00001331
View directory record Official record
Conditions
Dermatomyositis, Glycogen Storage Disease Type II, Glycogen Storage Disease Type VII, Myositis, Polymyositis
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Not listed
Healthy volunteers
Accepts healthy volunteers
Timeline
1993 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Jul 21, 2026, 2:17 PM EDT
Completed Not applicable Interventional Results available

Ultrasound in Muscle Biopsy

NCT01790178
View directory record Official record
Conditions
Myopathy, Myositis, Muscular Dystrophy
Interventions
Ultrasound
Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 1, 2017 · Synced Jul 21, 2026, 2:17 PM EDT
Completed Phase 2 Interventional

Methimazole to Treat Polymyositis and Dermatomyositis

NCT00001421
View directory record Official record
Conditions
Dermatomyositis, Polymyositis
Interventions
methimazole
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 21, 2026, 2:17 PM EDT
Completed Early Phase 1 Interventional

Double-blind, Randomized, Placebo-controlled Trial of Etanercept for 12 Months in Subjects With Inclusion Body Myositis

NCT00802815
View directory record Official record
Conditions
Inclusion Body Myositis
Interventions
Etanercept
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 28, 2014 · Synced Jul 21, 2026, 2:17 PM EDT
Recruiting No phase listed Observational

IL1 Inhibition in FOP

NCT06724562
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva (FOP)
Interventions
Anti-IL1 Therapy
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
6 Years to 30 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Jul 21, 2026, 2:17 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Belimumab in Idiopathic Inflammatory Myositis

NCT02347891
View directory record Official record
Conditions
Myositis
Interventions
Belimumab, Placebo
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Great Neck, New York
Source: ClinicalTrials.gov public record
Updated Feb 8, 2024 · Synced Jul 21, 2026, 2:17 PM EDT
Terminated Phase 3 Interventional Results available

Arimoclomol in Sporadic Inclusion Body Myositis - Open Label Extension Trial

NCT04049097
View directory record Official record
Conditions
Inclusion Body Myositis
Interventions
Arimoclomol
Drug
Lead sponsor
ZevraDenmark
Industry
Eligibility
45 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
11
States / cities
Phoenix, Arizona • Irvine, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Jul 21, 2026, 2:17 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The Effects of High Dose Fish Oil Supplementation on Delayed Onset Muscle Soreness and Inflammatory Markers

NCT00805870
View directory record Official record
Conditions
Muscle Damage, Muscle Inflammation
Interventions
Lovaza (omega-3-acid ethyl esters), Wheat Germ Oil
Drug
Lead sponsor
Western Michigan University
Other
Eligibility
18 Years to 30 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 4, 2012 · Synced Jul 21, 2026, 2:17 PM EDT
Recruiting No phase listed Observational

Rheumatology Diet Study

NCT06339957
View directory record Official record
Conditions
Diet Habit, Rheumatologic Disease, Autoimmune Diseases, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Dermatomyositis/polymyositis, Sjogren's Syndrome, Systemic Lupus Erythematous, Scleroderma, Fibromyalgia
Interventions
Not listed
Lead sponsor
University of Central Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Jul 21, 2026, 2:17 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Arimoclomol in Sporadic Inclusion Body Myositis

NCT00769860
View directory record Official record
Conditions
Inclusion Body Myositis
Interventions
Arimoclomol, Placebo
Drug · Other
Lead sponsor
Richard Barohn, MD
Other
Eligibility
50 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Jul 21, 2026, 2:17 PM EDT